Opinion
Innovative challengers are building compliance into their DNA and outcompeting established players.
The author is an independent contributor writing an opinion or expert take. Views expressed are the author’s own and may not reflect Cointelegraph’s editorial position. Michael Carbonara is the CEO of Ibanera and a business leader with experience navigating complex regulatory environments and establishing licenses globally. Michael is also a board member at Organicell Regenerative Medicine, Inc., and is the Co-Founder of Gattaca Genomics.
Innovative challengers are building compliance into their DNA and outcompeting established players.